Richard Carlson, OD
Optometrist · Valparaiso, INNPI 1073515938
Payments from drug & device makers
Across 54 payments — averaging $25.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$414
- Coopervision Inc.$340
- Johnson & Johnson Vision Care, Inc.$210
- Bausch & Lomb, A Division Of Bausch Health US, LLC$106
- Sun Pharmaceutical Industries Inc.$85
- AbbVie$62
- plus $187 from 6 others
What the payments were for
- Food & beverage$1,403100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 8 | $414 |
| Coopervision Inc. | 15 | $340 |
| Johnson & Johnson Vision Care, Inc. | 8 | $210 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 6 | $106 |
| Sun Pharmaceutical Industries Inc. | 5 | $85 |
| AbbVie(2 entities) | 3 | $62 |
| Kala Pharmaceuticals, Inc. | 3 | $54 |
| Shire North American Group Inc | 2 | $34 |
| Tarsus Pharmaceuticals, Inc. | 1 | $32 |
| Dompe US, Inc. | 1 | $30 |
| Genentech USA, Inc. | 1 | $23 |
| Bausch & Lomb Americas Inc. | 1 | $13 |
How this compares
$1,403 in reported general payments places this provider in the 70th percentile of 1,318 optometrist providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RocklatanNetarsudil Mesylat/Latanoprost | 20 | $10,053 |
| Prednisolone Acetate | 44 | $1,357 |
| Latanoprost | 262 | $1,275 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 88 | $1,109 |
| Trifluridine | 12 | $1,055 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 13 | $574 |
| Acyclovir | 42 | $506 |
| Brimonidine Tartrate | 46 | $200 |
| Timolol Maleate | 16 | $122 |
| ErythromycinErythromycin Base | 11 | $113 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 14 | $94 |
Paid to pharmacies, not to this prescriber.
Other optometrist in Valparaiso
- Peter KollbaumBloomington$8.3M
- Anna TichenorBloomington$872K
- Damon DierkerIndianapolis$826K
- Jason JedlickaBloomington$456K
- Kari RiinaFishers$308K
- Katherine SchuetzZionsville$303K
- Rhonda RobinsonIndianapolis$205K
- Kathleen KelleyIndianapolis$190K
- John CzajaMerrillville$189K
- Ryan GustusBluffton$48K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.